Mechanisms of immune evasion by tumors.

[1]  D. Gabrilovich,et al.  Role Of Immature Myeloid Cells in Mechanisms of Immune Evasion In Cancer , 2006, Cancer Immunology, Immunotherapy.

[2]  K. Taira,et al.  Effective inhibition of cell growth and invasion of melanoma by combined suppression of BRAF (V599E) and Skp2 with lentiviral RNAi , 2006, International journal of cancer.

[3]  Hua Yu,et al.  Inhibiting Stat3 signaling in the hematopoietic system elicits multicomponent antitumor immunity , 2005, Nature Medicine.

[4]  S. Sebti,et al.  Regulation of dendritic cell differentiation and antitumor immune response in cancer by pharmacologic-selective inhibition of the janus-activated kinase 2/signal transducers and activators of transcription 3 pathway. , 2005, Cancer research.

[5]  J. Turkson,et al.  A Novel Platinum Compound Inhibits Constitutive Stat3 Signaling and Induces Cell Cycle Arrest and Apoptosis of Malignant Cells* , 2005, Journal of Biological Chemistry.

[6]  B. Baban,et al.  A minor population of splenic dendritic cells expressing CD19 mediates IDO-dependent T cell suppression via type I IFN signaling following B7 ligation. , 2005, International immunology.

[7]  M. Croft.  The evolving crosstalk between co-stimulatory and co-inhibitory receptors: HVEM-BTLA. , 2005, Trends in immunology.

[8]  E. Jaffee,et al.  Recruitment of latent pools of high-avidity CD8+ T cells to the antitumor immune response , 2005, The Journal of experimental medicine.

[9]  B. Baban,et al.  GCN2 kinase in T cells mediates proliferative arrest and anergy induction in response to indoleamine 2,3-dioxygenase. , 2005, Immunity.

[10]  S. Rosenberg,et al.  TGF-β1 Attenuates the Acquisition and Expression of Effector Function by Tumor Antigen-Specific Human Memory CD8 T Cells , 2005, The Journal of Immunology.

[11]  S. Signoretti,et al.  Arginase-producing myeloid suppressor cells in renal cell carcinoma patients: a mechanism of tumor evasion. , 2005, Cancer research.

[12]  C. Drake,et al.  B and T Lymphocyte Attenuator Exhibits Structural and Expression Polymorphisms and Is Highly Induced in Anergic CD4+ T Cells 1 , 2005, The Journal of Immunology.

[13]  Ximing J. Yang,et al.  Adoptive transfer of tumor-reactive transforming growth factor-beta-insensitive CD8+ T cells: eradication of autologous mouse prostate cancer. , 2005, Cancer research.

[14]  G. Zhu,et al.  Blockade of B7-H1 and PD-1 by monoclonal antibodies potentiates cancer therapeutic immunity. , 2005, Cancer research.

[15]  R. Offringa,et al.  SPI-CI and SPI-6 cooperate in the protection from effector cell-mediated cytotoxicity. , 2005, Blood.

[16]  A. Ochsenbein.  Immunological ignorance of solid tumors , 2005, Springer Seminars in Immunopathology.

[17]  R. Weissleder,et al.  Regulatory T cells suppress tumor-specific CD8 T cell cytotoxicity through TGF-β signals in vivo , 2005 .

[18]  B. Baban,et al.  Specific subsets of murine dendritic cells acquire potent T cell regulatory functions following CTLA4-mediated induction of indoleamine 2,3 dioxygenase. , 2004, International immunology.

[19]  C. Drake,et al.  Role of LAG-3 in regulatory T cells. , 2004, Immunity.

[20]  V. Bronte,et al.  High-Dose Granulocyte-Macrophage Colony-Stimulating Factor-Producing Vaccines Impair the Immune Response through the Recruitment of Myeloid Suppressor Cells , 2004, Cancer Research.

[21]  E. Shevach.  Regulatory/suppressor T cells in health and disease. , 2004, Arthritis and rheumatism.

[22]  D. Pardoll,et al.  Cancer immunotherapy: breaking the barriers to harvest the crop , 2004, Nature Medicine.

[23]  George Coukos,et al.  Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival , 2004, Nature Medicine.

[24]  Michael Karin,et al.  IKKβ Links Inflammation and Tumorigenesis in a Mouse Model of Colitis-Associated Cancer , 2004, Cell.

[25]  B. Baban,et al.  Expression of indoleamine 2,3-dioxygenase by plasmacytoid dendritic cells in tumor-draining lymph nodes. , 2004, The Journal of clinical investigation.

[26]  Christopher J Bakkenist,et al.  Initiating Cellular Stress Responses , 2004, Cell.

[27]  J. Biggs,et al.  A Spontaneously Arising Pancreatic Tumor Does Not Promote the Differentiation of Naive CD8+ T Lymphocytes into Effector CTL1 , 2004, The Journal of Immunology.

[28]  R. Offringa,et al.  The Tumoricidal Activity of Memory CD8+ T Cells Is Hampered by Persistent Systemic Antigen, but Full Functional Capacity Is Regained in an Antigen-Free Environment1 , 2004, The Journal of Immunology.

[29]  Lieping Chen.  Co-inhibitory molecules of the B7–CD28 family in the control of T-cell immunity , 2004, Nature Reviews Immunology.

[30]  H. Ljunggren,et al.  Tumor necrosis factor receptor 1-mediated signaling is required for skin cancer development induced by NF-κB inhibition , 2004 .

[31]  J. Berzofsky,et al.  Immunoregulatory T cells in tumor immunity. , 2004, Current opinion in immunology.

[32]  D. Gabrilovich,et al.  Antigen-Specific Inhibition of CD8+ T Cell Response by Immature Myeloid Cells in Cancer Is Mediated by Reactive Oxygen Species1 , 2004, The Journal of Immunology.

[33]  R. Jove,et al.  Hyperactivation of STAT3 Is Involved in Abnormal Differentiation of Dendritic Cells in Cancer , 2004, The Journal of Immunology.

[34]  R. Steinman,et al.  Tolerogenic dendritic cells. , 2003, Annual review of immunology.

[35]  O. Finn,et al.  Cancer vaccines: between the idea and the reality , 2003, Nature Reviews Immunology.

[36]  S. Khoury,et al.  Critical Role of the Programmed Death-1 (PD-1) Pathway in Regulation of Experimental Autoimmune Encephalomyelitis , 2003, The Journal of experimental medicine.

[37]  Lieping Chen,et al.  Cooperative B7-1/2 (CD80/CD86) and B7-DC Costimulation of CD4+ T Cells Independent of the PD-1 Receptor , 2003, The Journal of experimental medicine.

[38]  S. Khoury,et al.  The Programmed Death-1 (PD-1) Pathway Regulates Autoimmune Diabetes in Nonobese Diabetic (NOD) Mice , 2003, The Journal of experimental medicine.

[39]  J. Allison,et al.  BTLA is a lymphocyte inhibitory receptor with similarities to CTLA-4 and PD-1 , 2003, Nature Immunology.

[40]  T. Honjo,et al.  CD4+ PD-1+ T cells accumulate as unique anergic cells in rheumatoid arthritis synovial fluid. , 2003, The Journal of rheumatology.

[41]  Thomas A. Davis,et al.  Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[42]  M. Colombo,et al.  IL-4-Induced Arginase 1 Suppresses Alloreactive T Cells in Tumor-Bearing Mice1 , 2003, The Journal of Immunology.

[43]  Michel C. Nussenzweig,et al.  Efficient Targeting of Protein Antigen to the Dendritic Cell Receptor DEC-205 in the Steady State Leads to Antigen Presentation on Major Histocompatibility Complex Class I Products and Peripheral CD8+ T Cell Tolerance , 2002, The Journal of experimental medicine.

[44]  Moses Rodriguez,et al.  Cross-linking the B7 Family Molecule B7-DC Directly Activates Immune Functions of Dendritic Cells , 2002, The Journal of experimental medicine.

[45]  J. Thompson,et al.  Adoptive T cell therapy using antigen-specific CD8+ T cell clones for the treatment of patients with metastatic melanoma: In vivo persistence, migration, and antitumor effect of transferred T cells , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[46]  D. Keskin,et al.  Potential Regulatory Function of Human Dendritic Cells Expressing Indoleamine 2,3-Dioxygenase , 2002, Science.

[47]  T. Eberlein,et al.  Prevalence of Regulatory T Cells Is Increased in Peripheral Blood and Tumor Microenvironment of Patients with Pancreas or Breast Adenocarcinoma1 , 2002, The Journal of Immunology.

[48]  Haidong Dong,et al.  Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion , 2002, Nature Medicine.

[49]  B. Olson,et al.  Inhibition of Transforming Growth Factor (TGF)- 1–Induced Extracellular Matrix with a Novel Inhibitor of the TGF- Type I Receptor Kinase Activity: SB-431542 , 2002 .

[50]  Peter A. Jones,et al.  The fundamental role of epigenetic events in cancer , 2002, Nature Reviews Genetics.

[51]  Andrew V. Nguyen,et al.  The Macrophage Growth Factor CSF-1 in Mammary Gland Development and Tumor Progression , 2002, Journal of Mammary Gland Biology and Neoplasia.

[52]  L. Ellis,et al.  Constitutive Stat3 activity up-regulates VEGF expression and tumor angiogenesis , 2002, Oncogene.

[53]  D. Speiser,et al.  Tumor Growth Enhances Cross-Presentation Leading to Limited T Cell Activation without Tolerance , 2002, The Journal of experimental medicine.

[54]  B. Clarke,et al.  Postmodern cancer: the role of human immunodeficiency virus in uterine cervical cancer , 2002, Molecular pathology : MP.

[55]  Christophe Caux,et al.  Tumour escape from immune surveillance through dendritic cell inactivation. , 2002, Seminars in cancer biology.

[56]  M. Byrne,et al.  CD4(+)CD25(+) immunoregulatory T cells: gene expression analysis reveals a functional role for the glucocorticoid-induced TNF receptor. , 2002, Immunity.

[57]  Ruth Lehr,et al.  Identification of novel inhibitors of the transforming growth factor beta1 (TGF-beta1) type 1 receptor (ALK5). , 2002, Journal of medicinal chemistry.

[58]  A. Visintin,et al.  Myeloid Suppressor Lines Inhibit T Cell Responses by an NO-Dependent Mechanism1 , 2002, The Journal of Immunology.

[59]  M W Kattan,et al.  Preoperative plasma levels of transforming growth factor β1 strongly predict clinical outcome in patients with bladder carcinoma , 2001, Cancer.

[60]  Michel C. Nussenzweig,et al.  Dendritic Cells Induce Peripheral T Cell Unresponsiveness under Steady State Conditions in Vivo , 2001, The Journal of experimental medicine.

[61]  T. Schumacher,et al.  Expression of the Serpin Serine Protease Inhibitor 6 Protects Dendritic Cells from Cytotoxic T Lymphocyte–Induced Apoptosis , 2001, The Journal of experimental medicine.

[62]  F. Marincola,et al.  Short-Term Kinetics of Tumor Antigen Expression in Response to Vaccination , 2001, The Journal of Immunology.

[63]  O. Finn,et al.  Activated granulocytes and granulocyte-derived hydrogen peroxide are the underlying mechanism of suppression of t-cell function in advanced cancer patients. , 2001, Cancer research.

[64]  T. Yeatman,et al.  Stat3-mediated Myc expression is required for Src transformation and PDGF-induced mitogenesis , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[65]  M. Kattan,et al.  Preoperative plasma levels of transforming growth factor beta(1) (TGF-beta(1)) strongly predict progression in patients undergoing radical prostatectomy. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[66]  E. Jaffee,et al.  Cyclophosphamide, doxorubicin, and paclitaxel enhance the antitumor immune response of granulocyte/macrophage-colony stimulating factor-secreting whole-cell vaccines in HER-2/neu tolerized mice. , 2001, Cancer research.

[67]  J. Buer,et al.  Fingerprints of anergic T cells , 2001, Current Biology.

[68]  D. Pardoll,et al.  B7-Dc, a New Dendritic Cell Molecule with Potent Costimulatory Properties for T Cells , 2001, The Journal of experimental medicine.

[69]  D. Gabrilovich,et al.  Human squamous cell carcinomas of the head and neck chemoattract immune suppressive CD34(+) progenitor cells. , 2001, Human immunology.

[70]  J. Egen,et al.  CTLA-4-mediated inhibition in regulation of T cell responses: mechanisms and manipulation in tumor immunotherapy. , 2001, Annual review of immunology.

[71]  T. Tsushima,et al.  Transforming growth factor‐β1 level correlates with angiogenesis, tumor progression, and prognosis in patients with nonsmall cell lung carcinoma , 2001 .

[72]  T. Okazaki,et al.  Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice. , 2001, Science.

[73]  R. Ronca,et al.  Identification of a CD11b(+)/Gr-1(+)/CD31(+) myeloid progenitor capable of activating or suppressing CD8(+) T cells. , 2000, Blood.

[74]  S. Dzik.  B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin 10 secretion , 2000 .

[75]  H. Lodish,et al.  Role of transforming growth factor beta in human disease. , 2000, The New England journal of medicine.

[76]  D. Carbone,et al.  Clinical significance of defective dendritic cell differentiation in cancer. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[77]  G. Fleuren,et al.  Multiple Genetic Alterations Cause Frequent and Heterogeneous Human Histocompatibility Leukocyte Antigen Class I Loss in Cervical Cancer , 2000, The Journal of experimental medicine.

[78]  R. Flavell,et al.  Abrogation of TGFβ Signaling in T Cells Leads to Spontaneous T Cell Differentiation and Autoimmune Disease , 2000 .

[79]  S. Tsujitani,et al.  The expression of transforming growth factor‐β1 is significantly correlated with the expression of vascular endothelial growth factor and poor prognosis of patients with advanced gastric carcinoma , 1999, Cancer.

[80]  S. Akira,et al.  Keratinocyte‐specific ablation of Stat3 exhibits impaired skin remodeling, but does not affect skin morphogenesis , 1999, The EMBO journal.

[81]  J. Darnell,et al.  Stat3 as an Oncogene , 1999, Cell.

[82]  S. Steinberg,et al.  Immune selection after antigen-specific immunotherapy of melanoma. , 1999, Surgery.

[83]  T. Honjo,et al.  Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor. , 1999, Immunity.

[84]  P. Klenerman,et al.  Immune surveillance against a solid tumor fails because of immunological ignorance. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[85]  F. Marincola,et al.  Natural variation of the expression of HLA and endogenous antigen modulates CTL recognition in an In vitro melanoma model , 1999, International journal of cancer.

[86]  H. Maguire,et al.  Tumor-induced interleukin-10 inhibits type 1 immune responses directed at a tumor antigen as well as a non-tumor antigen present at the tumor site. , 1999, Cancer research.

[87]  J. Altman,et al.  Viral Immune Evasion Due to Persistence of Activated T Cells Without Effector Function , 1998, The Journal of experimental medicine.

[88]  F. Brasseur,et al.  Mutations of the beta2-microglobulin gene result in a lack of HLA class I molecules on melanoma cells of two patients immunized with MAGE peptides. , 1998, Tissue antigens.

[89]  G. V. van Muijen,et al.  High expression of immunotherapy candidate proteins gp100, MART-1, tyrosinase and TRP-1 in uveal melanoma. , 1998, British Journal of Cancer.

[90]  B. Bogen,et al.  Clonal deletion of thymocytes as a tumor escape mechanism , 1998, International journal of cancer.

[91]  David W. Marsh,et al.  CD4+ T Cell Tolerance to Parenchymal Self-Antigens Requires Presentation by Bone Marrow–derived Antigen-presenting Cells , 1998, The Journal of experimental medicine.

[92]  J. Turkson,et al.  Stat3 Activation by Src Induces Specific Gene Regulation and Is Required for Cell Transformation , 1998, Molecular and Cellular Biology.

[93]  Anita B. Roberts,et al.  REGULATION OF IMMUNE RESPONSES BY TGF-β* , 1998 .

[94]  D. Pardoll,et al.  Induction of antigen-specific T cell anergy: An early event in the course of tumor progression. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[95]  F. Oesch,et al.  Immunoselection in vivo: Independent loss of MHC class I and melanocyte differentiation antigen expression in metastatic melanoma , 1997, International journal of cancer.

[96]  M. Pepper,et al.  Transforming growth factor-beta: vasculogenesis, angiogenesis, and vessel wall integrity. , 1997, Cytokine & growth factor reviews.

[97]  R. Biassoni,et al.  Major histocompatibility complex class I‐specific receptors on human natural killer and T lymphocytes , 1997, Immunological reviews.

[98]  F. Esteban,et al.  MHC class I antigens and tumour-infiltrating leucocytes in laryngeal cancer: long-term follow-up. , 1996, British Journal of Cancer.

[99]  F. Garrido,et al.  High frequency of altered HLA class I phenotypes in invasive colorectal carcinomas. , 1996, Tissue antigens.

[100]  F. Garrido,et al.  High frequency of altered HLA class I phenotypes in invasive breast carcinomas. , 1996, Human immunology.

[101]  R. S. Alpan,et al.  Cell cycle-dependent expression of TAP1, TAP2, and HLA-B27 messenger RNAs in a human breast cancer cell line. , 1996, Cancer research.

[102]  C. Scheibenbogen,et al.  Expression of gp100 in melanoma metastases resected before or after treatment with IFN alpha and IL-2. , 1996, Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy.

[103]  Allan Balmain,et al.  TGFβ1 Inhibits the Formation of Benign Skin Tumors, but Enhances Progression to Invasive Spindle Carcinomas in Transgenic Mice , 1996, Cell.

[104]  R. Tampé,et al.  Reduced membrane major histocompatibility complex class I density and stability in a subset of human renal cell carcinomas with low TAP and LMP expression. , 1996, Clinical cancer research : an official journal of the American Association for Cancer Research.

[105]  G. Fleuren,et al.  Association of allele-specific HLA expression and histopathologic progression of cervical carcinoma. , 1996, Gynecologic oncology.

[106]  L. Lanier,et al.  Inhibitory MHC class I receptors on NK cells and T cells. , 1996, Immunology today.

[107]  F. Marincola,et al.  Loss of functional beta 2-microglobulin in metastatic melanomas from five patients receiving immunotherapy. , 1996, Journal of the National Cancer Institute.

[108]  H. Griesser,et al.  Lymphoproliferative Disorders with Early Lethality in Mice Deficient in Ctla-4 , 1995, Science.

[109]  B. Bogen,et al.  Naive CD4+ T cells confer idiotype‐specific tumor resistance in the absence of antibodies , 1995, European Journal of Immunology.

[110]  F. Marincola,et al.  Loss of HLA class I antigens by melanoma cells: molecular mechanisms, functional significance and clinical relevance. , 1995, Immunology today.

[111]  M. Toda,et al.  Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. , 1995, Journal of immunology.

[112]  P. Itin,et al.  In situ analysis of transforming growth factor-βs (TGF-β1, TGF-β2, TGF-β3and TGF-3 type II receptor expression in malignant melanoma , 1995 .

[113]  J. Trowsdale,et al.  Restoration of endogenous antigen processing in Burkitt's lymphoma cells by Epstein‐Barr virus latent membrane protein‐1: coordinate up‐regulation of peptide transporters and HLA‐class I antigen expression , 1995, European journal of immunology.

[114]  M. Sanda,et al.  Molecular characterization of defective antigen processing in human prostate cancer. , 1995, Journal of the National Cancer Institute.

[115]  J. Sprent,et al.  T-cell apoptosis detected in situ during positive and negative selection in the thymus , 1994, Nature.

[116]  E. Jaffee,et al.  Role of bone marrow-derived cells in presenting MHC class I-restricted tumor antigens. , 1994, Science.

[117]  Xin Lu,et al.  Differential induction of transcriptionally active p53 following UV or lonizing radiation: Defects in chromosome instability syndromes? , 1993, Cell.

[118]  A. Houghton,et al.  Lack of HLA class I antigen expression by melanoma cells SK-MEL-33 caused by a reading frameshift in beta 2-microglobulin messenger RNA. , 1993, The Journal of clinical investigation.

[119]  R. Schwartz.  Costimulation of T lymphocytes: the role of CD28, CTLA-4, and B7/BB1 in interleukin-2 production and immunotherapy , 1992, Cell.

[120]  D. Longo,et al.  Alterations in signal transduction molecules in T lymphocytes from tumor-bearing mice. , 1992, Science.

[121]  T. Honjo,et al.  Induced expression of PD‐1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death. , 1992, The EMBO journal.

[122]  T. Boon,et al.  Mouse tumor rejection antigens P815A and P815B : Two epitopes carried by a single peptide , 1992, European journal of immunology.

[123]  F. Ramsdell,et al.  Maintenance of in Vivo Tolerance by Persistence of Antigen , 1992, Science.

[124]  M. Blackman,et al.  Major histocompatibility complex-restricted recognition of retroviral superantigens by V beta 17+ T cells , 1992, The Journal of experimental medicine.

[125]  J. Dausset,et al.  Altered binding of regulatory factors to HLA class I enhancer sequence in human tumor cell lines lacking class I antigen expression. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[126]  H. Petrie,et al.  Timing of deletion of autoreactive V beta 6+ cells and down-modulation of either CD4 or CD8 on phenotypically distinct CD4+8+ subsets of thymocytes expressing intermediate or high levels of T cell receptor. , 1991, International immunology.

[127]  F. Esteban,et al.  Lack of MHC class I antigens and tumour aggressiveness of the squamous cell carcinoma of the larynx. , 1990, British Journal of Cancer.

[128]  I. Figari,et al.  The autocrine production of transforming growth factor-beta 1 during lymphocyte activation. A study with a monoclonal antibody-based ELISA. , 1990, Journal of immunology.

[129]  B. Vogelstein,et al.  A genetic model for colorectal tumorigenesis , 1990, Cell.

[130]  P. Giacomini,et al.  Selective changes in expression of HLA class I polymorphic determinants in human solid tumors. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[131]  H. Koeppen,et al.  Tumor antigens defined by cloned immunological probes are highly polymorphic and are not detected on autologous normal cells , 1989, The Journal of experimental medicine.

[132]  F. Esteban,et al.  Histocompatibility antigens in primary and metastatic squamous cell carcinoma of the larynx , 1989, International journal of cancer.

[133]  M. Piris,et al.  Phenotypic expression of histocompatibility antigens in human primary tumours and metastases , 1989, Clinical & Experimental Metastasis.

[134]  R. Zinkernagel,et al.  T-cell receptor Vβ use predicts reactivity and tolerance to Mlsa- encoded antigens , 1988, Nature.

[135]  R. Walker,et al.  Immunohistochemical analysis of HLA antigens and mononuclear infiltrates of benign and malignant breast , 1987, The Journal of pathology.

[136]  R. Schwartz,et al.  Stimulation of normal inducer T cell clones with antigen presented by purified Ia molecules in planar lipid membranes: specific induction of a long-lived state of proliferative nonresponsiveness. , 1987, Journal of immunology.

[137]  P. Marrack,et al.  T cell tolerance by clonal elimination in the thymus , 1987, Cell.

[138]  D. Ruiter,et al.  HLA antigens in colorectal tumours--low expression of HLA class I antigens in mucinous colorectal carcinomas. , 1987, British Journal of Cancer.

[139]  M. Kripke,et al.  Stepwise immunologic selection of antigenic variants during tumor growth. , 1986, Journal of immunology.

[140]  H. Maguire,et al.  Induction of cell-mediated immunity to autologous melanoma cells and regression of metastases after treatment with a melanoma cell vaccine preceded by cyclophosphamide. , 1986, Cancer research.

[141]  F. Garrido,et al.  HETEROGENEITY OF THE EXPRESSION OF CLASS I AND II HLA ANTIGENS IN HUMAN BREAST CARCINOMA , 1986, Journal of immunogenetics.

[142]  H. Ljunggren,et al.  Selective rejection of H–2-deficient lymphoma variants suggests alternative immune defence strategy , 1986, Nature.

[143]  S. Segal,et al.  Abrogation of metastatic properties of tumour cells by de novo expression of H–2K antigens following H–2 gene transfection , 1985, Nature.

[144]  H. Ljunggren,et al.  Host resistance directed selectively against H-2-deficient lymphoma variants. Analysis of the mechanism , 1985, The Journal of experimental medicine.

[145]  S. Ferrone,et al.  Heterogeneous expression of melanoma-associated antigens and HLA antigens by primary and multiple metastatic lesions removed from patients with melanoma. , 1985, Cancer research.

[146]  J. Minna,et al.  Markedly decreased expression of class I histocompatibility antigens, protein, and mRNA in human small-cell lung cancer , 1985, The Journal of experimental medicine.

[147]  S. Ferrone,et al.  Distribution of human Class I (HLA-A,B,C) histocompatibility antigens in normal and malignant tissues of nonlymphoid origin. , 1984, Cancer research.

[148]  H. Whitwell,et al.  Expression of major histocompatibility antigens and leucocyte infiltration in benign and malignant human breast disease. , 1984, British Journal of Cancer.

[149]  S. Ferrone,et al.  Antigenic heterogeneity of skin tumors of nonmelanocyte origin: analysis with monoclonal antibodies to tumor-associated antigens and to histocompatibility antigens. , 1983, Journal of the National Cancer Institute.

[150]  H. Schreiber,et al.  Multiple tumour-specific antigens expressed on a single tumour cell , 1983, Nature.

[151]  C. Uyttenhove,et al.  Escape of mouse mastocytoma P815 after nearly complete rejection is due to antigen-loss variants rather than immunosuppression , 1983, The Journal of experimental medicine.

[152]  P. Engstrom,et al.  Augmentation of the human immune response by cyclophosphamide. , 1982, Cancer research.

[153]  R. North.  Cyclophosphamide-facilitated adoptive immunotherapy of an established tumor depends on elimination of tumor-induced suppressor T cells , 1982, The Journal of experimental medicine.

[154]  M. Kripke,et al.  Mechanisms of syngeneic tumor rejection. Susceptibility of host- selected progressor variants to various immunological effector cells , 1982, The Journal of experimental medicine.

[155]  C. Mckhann,et al.  ANTIGENIC SPECIFICITIES ON MURINE SARCOMA CELLS , 1971, The Journal of experimental medicine.

[156]  Melvin Cohn,et al.  A Theory of Self-Nonself Discrimination , 1970, Science.

[157]  M. Folan.  Immunological Tolerance , 1956, Journal of the Irish Medical Association.

[158]  H. von Boehmer,et al.  Mechanisms of suppression by suppressor T cells , 2005, Nature immunology.

[159]  C. Ware,et al.  B and T lymphocyte attenuator regulates T cell activation through interaction with herpesvirus entry mediator , 2005, Nature Immunology.

[160]  Michael Karin,et al.  NF-kappaB: linking inflammation and immunity to cancer development and progression. , 2005, Nature reviews. Immunology.

[161]  R. Weissleder,et al.  Regulatory T cells suppress tumor-specific CD8 T cell cytotoxicity through TGF-beta signals in vivo. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[162]  I. Egorov.  Mouse models of efficient and inefficient anti-tumor immunity, with emphasis on minimal residual disease and tumor escape , 2005, Cancer Immunology, Immunotherapy.

[163]  Hua Yu,et al.  Regulation of the innate and adaptive immune responses by Stat-3 signaling in tumor cells , 2004, Nature Medicine.

[164]  J. Cheville,et al.  Costimulatory B7-H1 in renal cell carcinoma patients: Indicator of tumor aggressiveness and potential therapeutic target. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[165]  H. Ljunggren,et al.  Tumor necrosis factor receptor 1-mediated signaling is required for skin cancer development induced by NF-kappaB inhibition. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[166]  R. Geffers,et al.  Frontline: Neuropilin‐1: a surface marker of regulatory T cells , 2004, European journal of immunology.

[167]  T. Tsushima,et al.  Transforming growth factor-beta1 level correlates with angiogenesis, tumor progression, and prognosis in patients with nonsmall cell lung carcinoma. , 2001, Cancer.

[168]  F. Marincola,et al.  Escape of human solid tumors from T-cell recognition: molecular mechanisms and functional significance. , 2000, Advances in immunology.

[169]  B. Bogen,et al.  Deletion of idiotype (Id)-specific T cells in multiple myeloma. , 2000, Acta oncologica.

[170]  R. Flavell,et al.  Abrogation of TGFbeta signaling in T cells leads to spontaneous T cell differentiation and autoimmune disease. , 2000, Immunity.

[171]  F. Marincola,et al.  Comparative analysis of the in vivo expression of tyrosinase, MART-1/Melan-A, and gp100 in metastatic melanoma lesions: implications for immunotherapy. , 1998, Journal of immunotherapy.

[172]  A. Roberts,et al.  Regulation of immune responses by TGF-beta. , 1998, Annual review of immunology.

[173]  S. Piantadosi,et al.  Immunomodulatory properties of antineoplastic drugs administered in conjunction with GM-CSF-secreting cancer cell vaccines. , 1998, International journal of oncology.

[174]  R. Schwartz.  T cell clonal anergy. , 1997, Current opinion in immunology.

[175]  H. Tesch,et al.  IL6 and IL6 receptor expression in Burkitt's lymphoma and lymphoblastoid cell lines: Promotion of IL6 receptor expression by EBV , 1995, Hematological oncology.

[176]  G. Fleuren,et al.  The expression of histocompatibility-related leukocyte antigens in the pathway to cervical carcinoma. , 1994, American journal of clinical pathology.

[177]  S. Ferrone,et al.  Lack of HLA class I antigen expression by cultured melanoma cells FO-1 due to a defect in B2m gene expression. , 1991, The Journal of clinical investigation.

[178]  A. Concha,et al.  Molecular analysis of MHC‐class‐I alterations in human tumor cell lines , 1991, International journal of cancer. Supplement = Journal international du cancer. Supplement.

[179]  F. Grosveld,et al.  Rejection of transplantable AKR leukaemia cells following MHC DNA-mediated cell transformation , 1984, Nature.